apomorphine has been researched along with istradefylline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koga, K; Kurokawa, M; Kuwana, Y; Nakamura, J; Ochi, M | 1 |
| Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA | 1 |
2 other study(ies) available for apomorphine and istradefylline
| Article | Year |
|---|---|
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Xanthines | 2000 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics | 2003 |